Becton, Dickinson and Company Prices Offerings Of $2.25 Billion Of Common Stock And $2.25 Billion Of Depositary Shares Representing Interests In Mandatory Convertible Preferred Stock Post author:Sam Post published:May 10, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Teligent Announces FDA Approval Of Erythromycin Topical Gel USP, 2% July 20, 2017 OWC Pharmaceutical Research Corp. Issues Chairman's Letter To Shareholders September 14, 2017 How This CRISPR Biotech Could Make Investors Rich December 26, 2017